Effect of Administering Intravenous Magnesium Sulfate on Fetal

Status Not yet recruiting

Clinical Trial Summary

Admission CTG for 20 minutes Settings on a CTG machine was standardised to enable a consistent approach of interpretation of traces. Paper speed of 3cm per minute will be adopted. Maternal heart rate was recorded and noted on CTG. Following birth date, time and mode of delivery will be labelled on CTG.

Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:

- Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.

- Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery.

Another 20 minutes CTG strip will be performed 20 minutes after administration of IV loading MgSO4, 7H2O and thus ensuring that MgSO4 has reached peak serum levels

Clinical Trial Description

Admission CTG:

Admission CTG will be performed for 20 minutes

I-Settings:

1. Settings on a CTG machine will be standardised to enable a consistent approach of interpretation of traces.

2. Paper speed of 3cm per minute will be adopted.

3. CTGs will be labelled with mother's name, hospital number.

4. Date and time settings on machines will be labelled at commencement of tracing.

5. Maternal heart rate will be recorded and noted on CTG.

6. Following birth date, time and mode of delivery will be labelled on CTG.

Magnesium Sulphate hepatahydrate administration:

Magnesium sulphate will be administered by continuous intravenous infusion according to our hospital protocol as follows:

- Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.

- Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery.

- Magnesium toxicity was monitored by hourly assessment of:

1. Patellar reflexes should be present.

2. Respiratory rate not < 16/min.

3. Urine output not < 100ml / hr. Another 20 minutes CTG strip will be performed 20 minutes after administration of IV loading MgSO4, 7H2O and thus ensuring that MgSO4 has reached peak serum levels ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03237000
Study type	Interventional
Source	Cairo University
Contact	Ahmed Maged, MD
Phone	01005227404
Email	prof.ahmedmaged@gmail.com
Status	Not yet recruiting
Phase	Phase 4
Start date	August 1, 2017
Completion date	January 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03510286` - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Recruiting	`NCT03313024` - Berlin-Brandenburg Pregnancy Cohort
Active, not recruiting	`NCT04990141` - Molecular Screening Method for Preeclampsia (PREMOM)
Completed	`NCT02147626` - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia	N/A
Not yet recruiting	`NCT05999851` - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy	N/A
Recruiting	`NCT02923206` - Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis	N/A
Not yet recruiting	`NCT02541110` - Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler	N/A
Completed	`NCT02554604` - Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
Completed	`NCT02854501` - Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
Terminated	`NCT02558023` - The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine	Phase 3
Completed	`NCT02384226` - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Withdrawn	`NCT05016440` - Lisinopril for Renal Protection in Postpartum Preeclamptic Women	N/A
Recruiting	`NCT02337049` - Preeclampsia Subtypes and Surrogate Markers of CVD Risk	N/A
Recruiting	`NCT02247297` - Pancreatic Stone Protein (PSP) in Pregnant Women
Completed	`NCT02238704` - Cornell University-Micronutrient Initiative Calcium Supplementation Study	N/A
Withdrawn	`NCT01179542` - The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR	N/A
Completed	`NCT01195441` - Prediction and Prevention of Preeclampsia by First Trimester Ultrasound	N/A
Completed	`NCT00456118` - Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
Recruiting	`NCT00117546` - Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia	Phase 4
Completed	`NCT00787241` - Platelet Count Trends in Pre-eclamptic Parturients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms